Gland Pharma Q1 Review - Complex Products, Newer Markets To Fortify Growth Pace: Motilal Oswal
An employee examines vials of injection solution inside a lab. (Photographer: Qilai Shen/Bloomberg)

Gland Pharma Q1 Review - Complex Products, Newer Markets To Fortify Growth Pace: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Gland Pharma Ltd.’s Q1 FY22 performance was ahead of our expectation, led by robust revenue growth across all geographies.

It is progressing well on scaling up manufacturing of the Covid-19 vaccine. It is concurrently developing products/undertaking capex related to complex product as well as enhancing its geographical diversification.

We raise our FY22E/FY23E earnings per share estimate of Gland Pharma by 8% each to factor in:

  1. increased reach as well as penetration in the rest of world/India markets,

  2. better outlook for the U.S. market,

  3. higher offtake of Remdesivir/Enoxaparin, and

  4. continued manufacturing efficiency driving better operating leverage.

Click on the attachment to read the full report:

Motilal Oswal Gland Pharma Q1FY22 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.